Search Results 821-830 of 17104 for monoclonal antibody

1. Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine - Mayo Clinic

   Receipt of any monoclonal antibody treatment (within or outside a clinical trial) within 6 months before screening. Previously dosed with ALD403 or any ...

2. A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma - Mayo Clinic

   2 cycles of an anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20 negative) and anthracycline-containing regimen (e.g., DA ...

3. Cholangiocarcinoma Clinical Trials - Mayo Clinic Research

   Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Cobimetinib may stop the growth of tumor ...

4. Clinical trials - Oncology (Medical)

   This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

5. A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment - Mayo Clinic

   ... monoclonal antibodies): 2 weeks; Immune-checkpoint inhibitors (i.e., anti-PD-1, anti-PD-L1, or anti-CTLA-4): 4 weeks; Other monoclonal antibodies, antibody ...

6. A Dose Escalation Study of HFB301001 in Adult Patients with Advanced Solid Tumors - Mayo Clinic

   composition to monoclonal antibodies or any excipient of HFB301001; - Known active malignancy, with the exception of the specific cancer under investigation

7. A Multicenter Assessment of ALD403 in Chronic Migraine - Mayo Clinic

   Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial); Previously dosed with ALD403 or any ...

8. Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production - Mayo Clinic

   - History of severe hypersensitivity to another monoclonal antibody - Other concurrent cancer or a history of another invasive malignancy within the last 3

9. A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab - Mayo Clinic

   ... antibody, avelumab, in selected advanced solid tumors. ... Known prior severe hypersensitivity reaction to monoclonal antibodies (grade ≥ 3 by NCI CTCAE v4.

10. An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

    An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in Patients with Relapsed or ...